Catalytic antibodies to HIV: Physiological role and potential clinical utility

Haase, 2005, Perils at mucosal front lines for HIV and SIV and their hosts, Nat Rev Immunol, 5, 783, 10.1038/nri1706 Cao, 1995, Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection, N Engl J Med, 332, 201, 10.1056/NEJM199501263320401 Devito, 2002, Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects, J Acquir Immune Defic Syndr, 30, 413, 10.1097/00042560-200208010-00007 Richman, 2004, HIV evolution and escape, Trans Am Clin Climatol Assoc, 115, 289 Moore, 1994, Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1, J Virol, 68, 5142, 10.1128/JVI.68.8.5142-5155.1994 Soudeyns, 1999, The moving target: mechanisms of HIV persistence during primary infection, Immunol Today, 20, 446, 10.1016/S0167-5699(99)01504-2 Pitisuttithum, 2006, Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand, J Infect Dis, 194, 1661, 10.1086/508748 Sekaly, 2008, The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?, J Exp Med, 205, 7, 10.1084/jem.20072681 Townsley-Fuchs, 1996, Human immunodeficiency virus-1 (HIV-1) gp120 superantigen-binding serum antibodies. A host factor in homosexual HIV-1 transmission, J Clin Invest, 98, 1794, 10.1172/JCI118979 Paul, 2004, Naturally occurring proteolytic antibodies: selective immunoglobulin M-catalyzed hydrolysis of HIV gp120, J Biol Chem, 279, 39611, 10.1074/jbc.M406719200 Planque, 2007, Characterization of gp120 Hydrolysis by IgA antibodies from humans without HIV infection, AIDS Res Hum Retroviruses, 23, 1541, 10.1089/aid.2007.0081 Karray, 1998, Structural basis of the gp120 superantigen-binding site on human immunoglobulins, J Immunol, 161, 6681, 10.4049/jimmunol.161.12.6681 Goodglick, 1995, Mapping the Ig superantigen-binding site of HIV-1 gp120, J Immunol, 155, 5151, 10.4049/jimmunol.155.11.5151 Juompan, 1998, Selective deficit in antibodies specific for the superantigen binding site of gp120 in HIV infection, Faseb J, 12, 1473, 10.1096/fasebj.12.14.1473 Patke, 2000, gp120- and TNF-alpha-induced modulation of human B cell function: proliferation, cyclic AMP generation, Ig production, and B-cell receptor expression, J Allergy Clin Immunol, 105, 975, 10.1067/mai.2000.105315 Sasano, 1993, Molecular selection of human antibodies with an unconventional bacterial B cell antigen, J Immunol, 151, 5822, 10.4049/jimmunol.151.10.5822 Nishiyama, 2007, Antibodies to the superantigenic site of HIV-1 gp120: hydrolytic and binding activities of the light chain subunit, Mol Immunol, 44, 2707, 10.1016/j.molimm.2006.12.005 Gao, 1995, Site-directed mutagenesis of proteolytic antibody light chain, J Mol Biol, 253, 658, 10.1006/jmbi.1995.0580 Paul, 2005, Antibodies as defensive enzymes, Springer Semin Immunopathol, 26, 485, 10.1007/s00281-004-0191-1 Olshevsky, 1990, Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding, J Virol, 64, 5701, 10.1128/JVI.64.12.5701-5707.1990 Taguchi, 2002, A mechanism-based probe for gp120-Hydrolyzing antibodies, Bioorg Med Chem Lett, 12, 3167, 10.1016/S0960-894X(02)00640-6 Gololobov, 1999, Innate antibody catalysis, Mol Immunol, 36, 1215, 10.1016/S0161-5890(99)00141-8 Silverman, 1998, B cell superantigens: possible roles in immunodeficiency and autoimmunity, Semin Immunol, 10, 43, 10.1006/smim.1997.0104 Bermas, 1994, Binding of glycoprotein 120 and peptides from the HIV-1 envelope by autoantibodies in mice with experimentally induced systemic lupus erythematosus and in patients with the disease, AIDS Res Hum Retroviruses, 10, 1071, 10.1089/aid.1994.10.1071 Karle, 2004, Cross-clade HIV-1 neutralization by an antibody fragment from a lupus phage display library, Aids, 18, 329, 10.1097/00002030-200401230-00026 Paul, 1989, Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody, Science, 244, 1158, 10.1126/science.2727702 Shuster, 1991, Dna-specific catalytic antibodies in human blood sera, Dokl Akad Nauk SSSR, 318, 1262 Sekigawa, 2000, The possible role of interleukin-16 in the low incidence of HIV infection in patients with systemic lupus erythematosus, Lupus, 9, 155, 10.1191/096120300678828136 Barthel, 1993, False-positive human immunodeficiency virus testing in patients with lupus erythematosus, Semin Arthritis Rheum, 23, 1, 10.1016/S0049-0172(05)80021-6 Urnovitz, 1996, Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease, Clin Microbiol Rev, 9, 72, 10.1128/CMR.9.1.72 Lyden, 1995, Expression of endogenous HIV-1 crossreactive antigens within normal human extravillous trophoblast cells, J Reprod Immunol, 28, 233, 10.1016/0165-0378(95)00924-A Holmes, 2001, On the origin and evolution of the human immunodeficiency virus (HIV), Biol Rev Camb Philos Soc, 76, 239, 10.1017/S1464793101005668 Mayer, 2005, Human endogenous retroviruses in the primate lineage and their influence on host genomes, Cytogenet Genome Res, 110, 448, 10.1159/000084977 Haigwood, 1996, Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile, Immunol Lett, 51, 107, 10.1016/0165-2478(96)02563-1 Mouthon, 2003, Intravenous immunoglobulins in infectious diseases: where do we stand?, Clin Microbiol Infect, 9, 333, 10.1046/j.1469-0691.2003.00694.x Berisha, 2002, New evidence for transmitter role of VIP in the airways: impaired relaxation by a catalytic antibody, Pulm Pharmacol Ther, 15, 121, 10.1006/pupt.2001.0337 Binley, 2004, Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies, J Virol, 78, 13232, 10.1128/JVI.78.23.13232-13252.2004 Paul, 2003, Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120, J Biol Chem, 278, 20429, 10.1074/jbc.M300870200 Nishiyama, 2006, Towards irreversible HIV inactivation: stable gp120 binding by nucleophilic antibodies, J Mol Recognit, 19, 423, 10.1002/jmr.795 Karle, 2003, Carrier-dependent specificity of antibodies to a conserved peptide determinant of gp120, Vaccine, 21, 1213, 10.1016/S0264-410X(02)00504-2